Breast cancers with amplification and/or overexpression of ERBB2 (also known as HER2) have a distinct transcriptional and genomic profile, confirming the central role that ERBB2 plays in the pathogenesis of this subtype of breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.